The 7th CSCO-CAHON-SITC Joint Symposium in Immuno-oncology

When:  Sep 27, 2017 from 14:30 to 16:10 (CST)

This event has already taken place.

Presented by
the Chinese Society of Clinical Oncology (CSCO) in collaboration with the Chinese American Hematologist and Oncologist Network (CAHON) and the Society for Immunotherapy of Cancer (SITC)

The 7th CSCO-CAHON-SITC Joint Symposium in Immuno-oncology was part of the CSCO 20th Annual Meeting on September 26 – 30, 2017.

This joint symposium provided information about the cancer immunotherapy landscape in China, emerging areas of research on immunotherapy, and clinical considerations for immunotherapy in the era of precision medicine. Expert speakers from CSCO, CAHON and SITC discussed cutting-edge topics, including ongoing clinical trials in China, immunotherapy combinations, and biomarkers to guide patient selection for immunotherapy.

Symposium Agenda

Symposium Co-chairs

Jin Li, MD, PhD – Fudan University Cancer Hospital, CSCO

Zihai Li, MD, PhD – Medical University of South Carolina, CAHON, SITC

2:30 – 2:35 p.m.      Overview of the Symposium - Immuno-oncology: The Fifth Pillar of Cancer              

                                Zihai Li, MD, PhD – Medical University of South Carolina, CAHON, SITC

Session I: Cancer Immunotherapy Landscape in China

2:35 – 2:50 p.m.       Cancer Immunotherapy: The Retrospect, Prospect & Challenges
                                 Bo Zhu, MD, PhD – Third Military Medical University Xinqiao Hospital, CSCO

2:50 – 3:05 p.m.       On-going Immunotherapy Clinical Trials in China
                                 Li Zhang, MD, PhD – Sun Yat-sen University Cancer Center, CSCO

Session II: Emerging Areas in Immuno-Oncology

3:05 – 3:20 p.m.      Rational Combination Immunotherapy of Cancer
Lei Zheng, MD, PhD – Johns Hopkins University, CAHON

3:20 – 3:35 p.m.      Novel Cancer Immunotherapy Approaches Utilizing Sequence-defined Neo-
Bruce Robinson, MBBS, MD – Sir Charles Gairdner Hospital, SITC

Session III: Cancer Immunotherapy in the Era of Precision Medicine

3:35 – 3:50 p.m.      How Emerging Biomarkers May Affect Patient Selection for Immunotherapy
Lisa Butterfield, PhD – University of Pittsburgh, SITC

3:50 – 4:05 p.m.      Clinical Considerations for Immunotherapy: The Regulatory Perspective
Ke Liu, MD, PhD – Food and Drug Administration (FDA), CAHON

4:05 – 4:10 p.m.      Conclusion – The Future of Immuno-oncology Is Now
Jin Li, MD, PhD – Tongji University Shanghai Eastern Hospital, CSCO

#InPersonEvent #Biomarkers #Collaboration #ClinicalTrials #Oncologist #SITC #Clinician #Researcher #CombinationTherapy #2017 #HotTopic #CollaborativeEvent #AnnualMeetingandPre-ConferencePrograms #Nurse


Xiamen International Conference and Exhibition Center
No. 198, Conference & Exhibition Rd, Siming District
Xiamen, Fujian, China, P.C:361008